Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2015
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 07 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.